Rhabdomyolysis and lipid-lowering drugs [2] (multiple letters)

JAMA

Volumn 293, Issue 12, 2005, Pages 1448-1449

  Tenenbaum, Alexander ^a   Fisman, Enrique Z ^a   Motro, Michael ^a   Graham, David J ^b   Staffa, Judy A ^b   La Grenade, Lois ^b   Shatin, Deborah ^c   Schech, Stephanie D ^c   Andrade, Susan E ^d   Gurwitz, Jerry H ^d   Goodman, Michael J ^e   Chan, K Arnold ^f   Platt, Richard ^f  

^a SHEBA MEDICAL CENTER   (Israel)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Ctr for Hlth Care Plcy and Eval   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; CLOFIBRIC ACID;

DIABETES MELLITUS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; HOSPITALIZATION; HUMAN; LETTER; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; NOTE; RISK;

ANTILIPEMIC AGENTS; CLOFIBRIC ACID; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RHABDOMYOLYSIS; RISK;

EID: 15044355141     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.12.1448-a     Document Type: Letter

References (0)